Iterum Therapeutics (ITRM) Income from Continuing Operations (2017 - 2022)
Historic Income from Continuing Operations for Iterum Therapeutics (ITRM) over the last 6 years, with Q4 2022 value amounting to -$5.1 million.
- Iterum Therapeutics' Income from Continuing Operations fell 2171.21% to -$5.1 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$44.4 million, marking a year-over-year increase of 5147.22%. This contributed to the annual value of -$25.1 million for FY2024, which is 3731.86% up from last year.
- Iterum Therapeutics' Income from Continuing Operations amounted to -$5.1 million in Q4 2022, which was down 2171.21% from -$29.1 million recorded in Q3 2022.
- In the past 5 years, Iterum Therapeutics' Income from Continuing Operations ranged from a high of $7.8 million in Q2 2021 and a low of -$98.9 million during Q1 2021
- For the 5-year period, Iterum Therapeutics' Income from Continuing Operations averaged around -$18.5 million, with its median value being -$14.1 million (2018).
- In the last 5 years, Iterum Therapeutics' Income from Continuing Operations surged by 16227.94% in 2021 and then tumbled by 87810.75% in 2022.
- Over the past 5 years, Iterum Therapeutics' Income from Continuing Operations (Quarter) stood at -$24.3 million in 2018, then grew by 0.54% to -$24.1 million in 2019, then soared by 50.75% to -$11.9 million in 2020, then soared by 64.8% to -$4.2 million in 2021, then dropped by 21.71% to -$5.1 million in 2022.
- Its Income from Continuing Operations stands at -$5.1 million for Q4 2022, versus -$29.1 million for Q3 2022 and -$6.7 million for Q2 2022.